ArticleMicrobiology spectrum2025
Identification of relevant analytical methods for adeno-associated virus stability assessment during formulation development.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Formulation development for gene therapy viral vectors requires high-performance analytical methods that indicate or predict virus stability. Additionally, if testing involves multiple excipients, sample throughput must be sufficiently high, and the method should require low amounts of virus material. These are challenging and sometimes conflicting requirements, especially in the analysis of adeno-associated viral vectors, which are currently the most prominent viral vectors in gene therapy development. In this exploratory study, we evaluated the ability of different analytical methods to indicate or predict the stability of the adeno-associated viral vectors and identified highly suitable techniques that fulfilled the requirements for analysis during formulation development. As functionality assays, such as reporter gene assays, are already established for rapid quality control assessments, they are not addressed in this study. From this study, we conclude that two methods have great potential to predict the stability of adeno-associated viral vectors: extrinsic differential scanning fluorimetry using SYBR Gold as a DNA binding fluorescent dye to detect genome release and nano differential scanning fluorimetry to investigate capsid unfolding behavior (based on intrinsic protein fluorescence). Size-exclusion chromatography, using multi-angle light scattering and UV detection, was found to be stability-indicating for particle size distribution and determining genome load of adeno-associated viral vectors.IMPORTANCEViral vectors are of growing importance in the areas of gene therapy, oncology, and vaccine development. However, these vectors are very unstable and usually have to be stored frozen at very low temperatures due to sub-optimal formulation conditions, in many cases. The development of superior formulations for viral vectors requires high-performance analytical methods. In this study, we evaluated relevant analytical methods with respect to sample throughput, material consumption, and applicability for viral vector formulation development. To our knowledge, this is the first time that methods for viral vector analysis were categorized according to their power to predict or indicate time-dependent long-term stability. This categorization of analytical methods is essential to rationalize, accelerate, and enhance the formulation development of viral vectors. Therefore, the studies in this article are prerequisites for the development of more stable viral vectors for gene therapy and vaccines and higher yields in manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.